Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1440496 | 0.98 | TSHR (0.42) | TSHRALDH1A1TDP1THRB | |
| SCHEMBL27822336 | 0.89 | ALDH1A1 (0.39) | TSHRALDH1A1 | |
| SCHEMBL6681446 | 0.82 | TSHR (0.41) | TSHRALDH1A1TDP1THRB | |
| SCHEMBL8176001 | 0.82 | TSHR (0.37) | TSHRALDH1A1TDP1 | |
| SCHEMBL27608071 | 0.79 | TSHR (0.37) | TSHRALDH1A1TDP1THRB | |
| SCHEMBL9578354 | 0.78 | ALDH1A1 (0.42) | TSHRALDH1A1TDP1THRB | |
| SCHEMBL1562829 | 0.78 | ALDH1A1 (0.46) | TSHRALDH1A1TDP1THRB | |
| SCHEMBL2597657 | 0.78 | ALDH1A1 (0.46) | TSHRALDH1A1TDP1THRB | |
| SCHEMBL1401750 | 0.78 | ALDH1A1 (0.46) | TSHRALDH1A1TDP1THRB | |
| Hydrochloric Acid SCHEMBL5722210 | 0.78 | TSHR (0.39) | TSHRALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101636153-A | Time-specific delayed/pulsatile release dosage forms | POLICHEM SA | 2010-01-27 | — | — | CN | claimed |
| EP-0415671-B1 | Gastric retention device | YAMANOUCHI PHARMA CO LTD (JP) | 1995-03-29 | — | — | EP | claimed |
| EP-0415671-A2 | Gastric retention device | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1991-03-06 | — | — | EP | claimed |
| US-10639257-B2 | Composition for colouring keratin fibres | BEAUTY & BUSINESS S.P.A. (IT) | 2020-05-05 | — | — | US | disclosed |
| US-20190117541-A1 | COMPOSITION FOR COLOURING KERATIN FIBRES | BEAUTY & BUSINESS S.P.A. (IT) | 2019-04-25 | — | — | US | disclosed |
| EP-2838512-B1 | TAMPER RESISTANT AND DOSE-DUMPING RESISTANT PHARMACEUTICAL DOSAGE FORM | GRUENENTHAL GMBH (DE) | 2018-08-22 | — | — | EP | disclosed |
| US-20170296472-A1 | Tamper resistant dosage form with bimodal release profile | Grünenthal GmbH (DE) | 2017-10-19 | — | — | US | disclosed |
| US-20160317408-A1 | KERATIN FIBRE DYEING METHOD | ALFA PARF GROUP S.P.A. (IT) | 2016-11-03 | — | — | US | disclosed |
| EP-2838512-A1 | TAMPER RESISTANT AND DOSE-DUMPING RESISTANT PHARMACEUTICAL DOSAGE FORM | Grünenthal GmbH (DE) | 2015-02-25 | — | — | EP | disclosed |
| CN-103917231-A | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof | PHARMACYCLICS INC | 2014-07-09 | — | — | CN | disclosed |
| CN-103402515-A | Sgc stimulators | IRONWOOD PHARMACEUTICALS INC | 2013-11-20 | — | — | CN | disclosed |
| CN-101310703-A | Foamable alcoholic compositions | GOJO IND INC (US) | 2008-11-26 | — | — | CN | disclosed |
| EP-1203590-B1 | SOLID PREPARATIONS CONTAINING CHITOSAN POWDER AND PROCESS FOR PRODUCING THE SAME | DAINIPPON SUMITOMO PHARMA CO (JP) | 2007-07-04 | — | — | EP | disclosed |
| CN-1863511-A | Dosage forms providing controlled release cholesteryl ester transfer protein inhibitors and immediate release HMG-CoA reductase inhibitors | PFIZER (US) | 2006-11-15 | — | — | CN | disclosed |
| US-20050169990-A1 | Controlled release dosage forms using acrylic polymer, and process for making | ENDO PHARMACEUTICALS INC. | 2005-08-04 | — | — | US | disclosed |
| CN-1625397-A | Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor | PFIZER PROD INC (US) | 2005-06-08 | — | — | CN | disclosed |
| EP-1392250-A2 | CONTROLLED RELEASE DOSAGE FORMS USING ACRYLIC POLYMER, AND PROCESS FOR MAKING THE SAME | Endo Pharmaceuticals Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2003105905-A1 | CONTROLLED RELEASE COMPOSITION COMPRISING FELODIPINE AND METHOD OF PREPARATION THEREOF | WHAN IN PHARM. CO., LTD. (KR) | 2003-12-24 | — | — | WO | disclosed |
| WO-2002100382-A2 | CONTROLLED RELEASE DOSAGE FORMS USING ACRYLIC POLYMER, AND PROCESS FOR MAKING THE SAME | ENDO PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-0447168-A2 | Long acting granular pharmaceutical composition | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1991-09-18 | — | — | EP | disclosed |